OCTASA is a brand of medication primarily used in the treatment and management of mild to moderate ulcerative colitis, a form of inflammatory bowel disease that affects the lining of the large intestine and rectum. It contains mesalazine (also known as mesalamine or 5-aminosalicylic acid) as its active ingredient, which works by reducing inflammation in the colon, helping to control symptoms and prevent flare-ups of the condition. OCTASA is formulated in delayed-release tablets or granules, designed to ensure that the medication is released specifically in the colon where its anti-inflammatory action is needed. This targeted delivery helps to maximize the effectiveness of the medication while minimizing potential side effects. It is important for patients to follow their healthcare provider's instructions when taking OCTASA to ensure its efficacy and safety.